Provided by Tiger Trade Technology Pte. Ltd.

Theravance Biopharma

16.06
-0.1500-0.93%
Post-market: 16.060.00000.00%17:40 EDT
Volume:531.20K
Turnover:8.56M
Market Cap:826.98M
PE:7.26
High:16.25
Open:16.21
Low:16.00
Close:16.21
52wk High:21.03
52wk Low:9.16
Shares:51.49M
Float Shares:21.84M
Volume Ratio:1.60
T/O Rate:2.43%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.21
EPS(LYR):2.06
ROE:50.17%
ROA:0.76%
PB:2.85
PE(LYR):7.80

Loading ...

Theravance Biopharma Down Nearly 27%, On Pace for Largest Percent Decrease Since August 2021 -- Data Talk

Dow Jones
·
Mar 04

Top Midday Decliners

MT Newswires Live
·
Mar 04

BUZZ-U.S. STOCKS ON THE MOVE-Versant Media Group, Lithium miners, Expedia Group

Reuters
·
Mar 04

Theravance Biopharma Plummets As Phase 3 Study Falls Short

Benzinga
·
Mar 04

Theravance Biopharma Is Maintained at Buy by BTIG

Dow Jones
·
Mar 04

Theravance Biopharma price target lowered to $21 from $40 at BTIG

TIPRANKS
·
Mar 04

BUZZ-U.S. STOCKS ON THE MOVE-Expedia Group, Blue Owl Capital, Enphase Energy

Reuters
·
Mar 03

BUZZ-Theravance falls as co weighs options including possible sale after drug trial failure

Reuters
·
Mar 03

Theravance to Cut 50% of Workforce in Cost-Savings Push, Wind Down Late-Stage Program

Dow Jones
·
Mar 03

Theravance Biopharma falls 28% to $13.55 in pre-market trading

TIPRANKS
·
Mar 03

Theravance Biopharma implements cost reduction actions after study results

TIPRANKS
·
Mar 03

Theravance Biopharma Restructures After Ampreloxetine Trial Failure

TIPRANKS
·
Mar 03

Theravance Biopharma Shares Fall 28% Premarket After Blood Pressure Drug Does Not Meet Goal in Late-Stage Trial, Co Plans Strategic Review

THOMSON REUTERS
·
Mar 03

Theravance considers possible sale after drug trial setback

Reuters
·
Mar 03

Theravance Biopharma trading halted, news pending

TIPRANKS
·
Mar 03

BRIEF-Theravance Biopharma Reports Phase 3 Cypress Study Did Not Meet Primary Endpoint Board Accelerates Strategic Review And Announces Cost Reduction Actions

Reuters
·
Mar 03

Theravance Biopharma launches restructuring to cut costs by 60%

Reuters
·
Mar 03

Theravance Biopharma Inc: Strategic Review Committee Accelerating Ongoing Efforts to Evaluate Alternatives to Maximize Shareholder Value

THOMSON REUTERS
·
Mar 03

Theravance Biopharma Inc: Reduction Includes Complete Wind-Down of R&D Organization and a Decrease of Approximately 50% in G&a Employees

THOMSON REUTERS
·
Mar 03

Theravance Biopharma Inc: Restructuring Expected to Result in Company Generating Approximately $60 - $70 Mln of Annualized Cash Flow

THOMSON REUTERS
·
Mar 03